顶部logo
顶部logo
more_1

home

ホーム > レポート一覧 > 一般用抗感染症薬の世界市場規模、シェア、企業ランキング、売上、需要動向予測（2026～2032年）

一般用抗感染症薬の世界市場規模、シェア、企業ランキング、売上、需要動向予測（2026～2032年）

OTC Anti-Infective Products- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
  • レポートID：
    81034
  • 発表時期：
    2026-01-05
  • レポート形式：
    PDF
  • 産業カテゴリー：
    薬品及びサプリメント
  • レポート言語：
    英語、日本語
  • ページ数：
    124
  • 発行会社（調査会社）：
    QYResearch
title

言語とエディションの価格

  • 英語版
  • 日本語版
  • 英語と日本語版

個人版詳細

マルチユーザー版詳細

企業版詳細

  • 英語版
  • 日本語版
  • 英語と日本語版

価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=159.00円。

※米ドル表示価格+10％消費税。

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

title

レポートの概要

本報告書は、世界の一般用抗感染症薬市場について包括的な分析を行い、市場全体の動向を明らかにすることを目的としています。総販売数量、売上高、価格動向に加え、主要企業の市場シェアおよび順位を整理し、市場構造を多角的に把握します。さらに、地域・国別、製品タイプ別、用途分野別などの観点から一般用抗感染症薬市場を分析し、需要構造と成長特性を明確化します。
一般用抗感染症薬市場の規模、推定値および予測は、2025年を基準年とし、2021年から2032年までの期間における販売数量および売上高に基づいて提示しています。定量分析と定性分析を組み合わせることで、ビジネスおよび成長戦略を検討し、市場競争環境を評価し、企業の市場ポジションを把握した上で、一般用抗感染症薬に関する的確な意思決定を行うための実践的なインサイトを提供します。
 主要一般用抗感染症薬市場の統計
2025年世界市場規模：14670百万米ドル
2026年世界市場規模：15120百万米ドル
2032年予測市場規模：18480百万米ドル
2026–2032年予測期間CAGR：3.4%
本レポートは一般用抗感染症薬市場の中長期的な成長動向を定量分析および定性分析の両面から体系的に整理しています。 
【市場セグメンテーション】
主要企業・競争環境
一般用抗感染症薬市場の主要企業には以下が含まれます：
Bayer
GSK
Teva
Johnson & Johnson
NOVARTIS
MYLAN
Sun Pharma
CR SANJIU
Cipla
Lingrui
Gilead Sciences
Pfizer
Bausch Health
Astellas Pharma
Roche 

製品別
Antifungal
Antibacterial
Antiviral
Antiseptics
Others 

アプリケーション別
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies 

レポート対象地域
北米：アメリカ、カナダ、その他
アジア太平洋：中国、日本、韓国、東南アジア、インド、オーストラリア、その他
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、オランダ、北欧諸国、その他
ラテンアメリカ：メキシコ、ブラジル、その他
中東・アフリカ：トルコ、サウジアラビア、UAE、その他

レポート構成（章別概要）
第1章｜市場概要と成長展望
一般用抗感染症薬市場の全体像を整理し、市場規模、売上予測、価格推移を体系的に解説します。同時に成長要因、市場機会、業界課題、リスク要因を分析し、中長期的な市場展望を提示します
第2章｜主要企業の競争分析
一般用抗感染症薬市場における主要プレイヤー（トップ5社・トップ10社）を対象に、売上高、製造拠点、製品構成、価格戦略、販売量、市場シェアを多面的に分析し、競争構造を明確化します
第3章｜製品カテゴリ別市場動向
製品タイプ別に一般用抗感染症薬市場を分類し、売上高、市場シェア、販売量、価格動向を分析します。成長性の高い製品分野と市場構造の変化を明らかにします
第4章｜用途別市場動向
用途別に一般用抗感染症薬市場規模、売上高、市場シェア、販売量、価格推移を整理し、業界別の需要動向と成長ポテンシャルを分析します
第5章｜地域別市場分析
地域別の市場成長率、販売量、売上高を詳細に分析し、一般用抗感染症薬市場の地理的需要構造を可視化します。各地域の市場規模推移と将来の成長余地を評価します
第6章｜国別市場動向
主要国・地域ごとに、一般用抗感染症薬市場の販売量、売上高、成長要因、政策・規制環境、競争特性を整理し、国別市場の特徴を明確にします
第7章｜主要企業プロファイル
一般用抗感染症薬市場を牽引する主要企業について、売上高、販売量、価格動向、粗利益率、製品ポートフォリオ、最新の戦略動向を詳細に解説します
第8章｜バリューチェーンと市場構造分析
業界全体のサプライチェーンを上流から下流まで整理し、コスト構造や流通モデルの動向を分析します
第9章｜調査結果
調査結果を総括し、市場全体のトレンド、今後の成長機会、潜在的リスク、戦略的な洞察を提示します
第10章｜付録（調査手法・データソース）
調査設計、分析手法、使用データソースの詳細を明示し、レポートの信頼性と透明性を担保します

本レポートの要点と洞察
●一般用抗感染症薬市場の全体像と成長見通し
一般用抗感染症薬市場の規模変化の傾向、成長予測及び需要動向を体系的に整理いたします。2021年から2025年までの実績データに基づき、2032年までの中長期予測を提示し、市場の拡大速度と成長潜在力を明らかにします。同時に、最近の関税調整措置など各国の政策動向を踏まえ、多角的にグローバル経済環境が一般用抗感染症薬市場に与える影響を分析いたします。
●市場環境の構成要素とマクロトレンド
一般用抗感染症薬産業を取り巻く市場環境について、需要構造の変化、政策対応、技術革新の進展といった主要要因を整理します。特に、国際貿易政策や関税政策の変化が企業戦略や価格形成に及ぼす影響、サプライチェーン再編の動きと事業運営への波及効果を明確化し、市場環境の全体像を包括的に提示します。
●競争構造と主要企業の動向分析
一般用抗感染症薬市場における主要企業の売上規模、市場シェア、競争ポジションを整理し、競争構造の特徴を分析します。各社の競争戦略、事業拡大の方向性、新製品・新技術の投入動向を通じて、技術革新が市場競争に与える影響と競争環境の変化を解読します。
●競争環境と事業動向の把握
製品タイプ別、用途別、地域・国別の観点から一般用抗感染症薬市場のセグメント構造を整理します。各地域の需要構成と成長特性を比較分析し、各細分領域が市場全体の成長に与える貢献度と相互関連性を明確にします。
●成長要因・課題・リスクの分析
一般用抗感染症薬市場の成長を支える主要ドライバーを整理するとともに、業界特有の課題や潜在的リスクを分析します。原材料調達、供給システム、事業運営における不確実性を踏まえ、サプライチェーン及び事業レジリエンス強化の方向性についても考察します。
●将来トレンドと市場展望
一般用抗感染症薬市場の中長期的な成長トレンドと将来の発展シナリオを提示します。持続的成長を実現するための重要な成功要因を整理し、今後の市場参入企業や既存プレイヤーの戦略的意思決定に参考となる視点を提供いたします。
title

Description

The global market for OTC Anti-Infective Products was estimated to be worth US$ 14670 million in 2025 and is projected to reach US$ 18480 million, growing at a CAGR of 3.4% from 2026 to 2032.

The potential shifts in the 2025 U.S. tariff framework pose substantial volatility risks to global markets. This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on OTC Anti-Infective Products cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
Anti-infectives are medicines that work to prevent or treat infections. Anti-infective drugs used for the purpose of killing or suppressing the infection causing organisms from invading the host by means of its replication or releasing variety of toxins into the host. Infection causing micro-organisms include bacteria, viruses, fungi, viroids, and macro parasites.

The OTC anti-infective products market is driven by the growing consumer demand for accessible and affordable healthcare solutions. With increasing awareness of self-care and the rising prevalence of minor infections like cuts, burns, and fungal conditions, consumers are turning to OTC products for quick relief and convenience. Additionally, the expansion of retail pharmacy chains and e-commerce platforms has improved the availability of OTC anti-infective products globally, further boosting market growth. Innovations in formulations, such as faster-acting and longer-lasting products, also contribute to market demand.

Despite its growth, the market faces challenges, including the risk of misuse or overuse of OTC anti-infective products, which can lead to antimicrobial resistance (AMR). Regulatory scrutiny is also increasing to ensure product safety and efficacy, which may delay product approvals and raise costs for manufacturers. Moreover, competition from alternative treatments, such as natural remedies or prescription medications, may limit the market potential for OTC anti-infective products, particularly in regions with stricter healthcare regulations.

Global core OTC anti-infective products manufacturers include Teva, MYLAN and NOVARTIS etc. The Top 3 companies hold a share above 10%. Asia-Pacific is the largest market, with a share about 38%, followed by North America and Europe with the share about 30% and 20%.

This report provides a comprehensive view of the global market for OTC Anti-Infective Products, covering total sales volume, sales revenue, pricing, the market share and ranking of key companies, along with analyses by region & country, by Type, and by Sales Channel.

The OTC Anti-Infective Products market size, estimations, and forecasts are presented in terms of sales volume (M Units) and revenue ($ millions), with 2025 as the base year and historical and forecast data from 2021 to 2032. The report combines quantitative and qualitative analysis to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current marketplace, and make informed business decisions regarding OTC Anti-Infective Products.

Market Segmentation
By Company
    Bayer
    GSK
    Teva
    Johnson & Johnson
    NOVARTIS
    MYLAN
    Sun Pharma
    CR SANJIU
    Cipla
    Lingrui
    Gilead Sciences
    Pfizer
    Bausch Health
    Astellas Pharma
    Roche

Segment by Type
    Antifungal
    Antibacterial
    Antiviral
    Antiseptics
    Others

Segment by Sales Channel
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies

By Region
    North America
    Europe
    China
    India
    Japan

Consumption by Region
    North America
        United States
        Canada
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        Rest of Asia-Pacific
    Europe
        Germany
        France
        U.K.
        Italy
        Netherlands
        Nordic Countries
        Rest of Europe
    Latin America
        Mexico
        Brazil
        Rest of Latin America
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
        Rest of MEA

Chapter Outline
Chapter 1: Introduces the scope of the report and the global market size (value, volume, and price). It also summarizes market dynamics and Recent Developments; identifies key drivers and restraints; outlines challenges and risks for manufacturers; reviews relevant industry policies and U.S. tariff implications.
Chapter 2: Provides a detailed analysis of the OTC Anti-Infective Products manufacturers' competitive landscape—including pricing, sales and revenue shares, Recent Developments plans, and mergers and acquisitions (M&A).
Chapter 3: Analyzes market segmentation by Type, presenting the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 4: Analyzes market segmentation by Sales Channel, presenting the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 5: Presents OTC Anti-Infective Products sales and revenue at the regional level. It offers a quantitative assessment of market size and growth potential by region and summarizes market development, future prospects, addressable space, and country-level market size worldwide.
Chapter 6: Presents OTC Anti-Infective Products sales and revenue at the country level. It provides segmented data by Type and by Sales Channel for each country/region.
Chapter 7: Profiles key players, detailing the main companies' product sales, revenue, pricing, gross margin, product portfolios, Recent Developments, etc.
Chapter 8: Analyzes the industry value chain, including upstream suppliers and downstream applications/customers.
Chapter 9: Conclusion.
title

Table of Contents

1 Market Overview
    1.1 OTC Anti-Infective Products Product Introduction
    1.2 Global OTC Anti-Infective Products Market Size Forecast
        1.2.1 Global OTC Anti-Infective Products Sales Value (2021–2032)
        1.2.2 Global OTC Anti-Infective Products Sales Volume (2021–2032)
        1.2.3 Global OTC Anti-Infective Products Sales Price (2021–2032)
    1.3 OTC Anti-Infective Products Market Trends & Drivers
        1.3.1 OTC Anti-Infective Products Industry Trends
        1.3.2 OTC Anti-Infective Products Market Drivers & Opportunities
        1.3.3 OTC Anti-Infective Products Market Challenges
        1.3.4 OTC Anti-Infective Products Market Restraints
        1.3.5 Impact of U.S. Tariffs
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered
2 Competitive Analysis by Company
    2.1 Global OTC Anti-Infective Products Players Revenue Ranking (2025)
    2.2 Global OTC Anti-Infective Products Revenue by Company (2021–2026)
    2.3 Global OTC Anti-Infective Products Sales Volume Ranking of Players (2025)
    2.4 Global OTC Anti-Infective Products Sales Volume by Company (2021–2026)
    2.5 Global OTC Anti-Infective Products Average Price by Company (2021–2026)
    2.6 Key Manufacturers OTC Anti-Infective Products Manufacturing Base and Headquarters
    2.7 Key Manufacturers OTC Anti-Infective Products Product Offerings
    2.8 Key Manufacturers Start of Mass Production of OTC Anti-Infective Products
    2.9 OTC Anti-Infective Products Market Competitive Analysis
        2.9.1 OTC Anti-Infective Products Market Concentration Rate (2021–2026)
        2.9.2 Global 5 and 10 Largest Manufacturers by OTC Anti-Infective Products Revenue in 2025
        2.9.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on OTC Anti-Infective Products revenue, 2025
    2.10 Mergers & Acquisitions and Expansion
3 Segmentation OTC Anti-Infective Products Market Classification
    3.1 Introduction by Type
        3.1.1 Antifungal
        3.1.2 Antibacterial
        3.1.3 Antiviral
        3.1.4 Antiseptics
        3.1.5 Others
        3.1.6 Global OTC Anti-Infective Products Sales Value by Type
            3.1.6.1 Global OTC Anti-Infective Products Sales Value by Type (2021 vs 2025 vs 2032)
            3.1.6.2 Global OTC Anti-Infective Products Sales Value, by Type (2021–2032)
            3.1.6.3 Global OTC Anti-Infective Products Sales Value, by Type (%), 2021–2032
        3.1.7 Global OTC Anti-Infective Products Sales Volume by Type
            3.1.7.1 Global OTC Anti-Infective Products Sales Volume by Type (2021 vs 2025 vs 2032)
            3.1.7.2 Global OTC Anti-Infective Products Sales Volume, by Type (2021–2032)
            3.1.7.3 Global OTC Anti-Infective Products Sales Volume, by Type (%), 2021–2032
        3.1.8 Global OTC Anti-Infective Products Average Price by Type (2021–2032)
4 Segmentation by Sales Channel
    4.1 Introduction by Sales Channel
        4.1.1 Hospital Pharmacies
        4.1.2 Retail Pharmacies
        4.1.3 Online Pharmacies
    4.2 Global OTC Anti-Infective Products Sales Value by Sales Channel
        4.2.1 Global OTC Anti-Infective Products Sales Value by Sales Channel (2021 vs 2025 vs 2032)
        4.2.2 Global OTC Anti-Infective Products Sales Value, by Sales Channel (2021–2032)
        4.2.3 Global OTC Anti-Infective Products Sales Value, by Sales Channel (%), 2021–2032
    4.3 Global OTC Anti-Infective Products Sales Volume by Sales Channel
        4.3.1 Global OTC Anti-Infective Products Sales Volume by Sales Channel (2021 vs 2025 vs 2032)
        4.3.2 Global OTC Anti-Infective Products Sales Volume, by Sales Channel (2021–2032)
        4.3.3 Global OTC Anti-Infective Products Sales Volume, by Sales Channel (%), 2021–2032
    4.4 Global OTC Anti-Infective Products Average Price by Sales Channel (2021–2032)
5 Segmentation by Region
    5.1 Global OTC Anti-Infective Products Sales Value by Region
        5.1.1 Global OTC Anti-Infective Products Sales Value by Region: 2021 vs 2025 vs 2032
        5.1.2 Global OTC Anti-Infective Products Sales Value by Region (2021–2026)
        5.1.3 Global OTC Anti-Infective Products Sales Value by Region (2027–2032)
        5.1.4 Global OTC Anti-Infective Products Sales Value by Region (%), 2021–2032
    5.2 Global OTC Anti-Infective Products Sales Volume by Region
        5.2.1 Global OTC Anti-Infective Products Sales Volume by Region: 2021 vs 2025 vs 2032
        5.2.2 Global OTC Anti-Infective Products Sales Volume by Region (2021–2026)
        5.2.3 Global OTC Anti-Infective Products Sales Volume by Region (2027–2032)
        5.2.4 Global OTC Anti-Infective Products Sales Volume by Region (%), 2021–2032
    5.3 Global OTC Anti-Infective Products Average Price by Region (2021–2032)
    5.4 North America
        5.4.1 North America OTC Anti-Infective Products Sales Value, 2021–2032
        5.4.2 North America OTC Anti-Infective Products Sales Value by Country (%), 2025 vs 2032
    5.5 Europe
        5.5.1 Europe OTC Anti-Infective Products Sales Value, 2021–2032
        5.5.2 Europe OTC Anti-Infective Products Sales Value by Country (%), 2025 vs 2032
    5.6 Asia Pacific
        5.6.1 Asia Pacific OTC Anti-Infective Products Sales Value, 2021–2032
        5.6.2 Asia Pacific OTC Anti-Infective Products Sales Value by Region (%), 2025 vs 2032
    5.7 South America
        5.7.1 South America OTC Anti-Infective Products Sales Value, 2021–2032
        5.7.2 South America OTC Anti-Infective Products Sales Value by Country (%), 2025 vs 2032
    5.8 Middle East & Africa
        5.8.1 Middle East & Africa OTC Anti-Infective Products Sales Value, 2021–2032
        5.8.2 Middle East & Africa OTC Anti-Infective Products Sales Value by Country (%), 2025 vs 2032
6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions OTC Anti-Infective Products Sales Value Growth Trends, 2021 vs 2025 vs 2032
    6.2 Key Countries/Regions OTC Anti-Infective Products Sales Value and Sales Volume
        6.2.1 Key Countries/Regions OTC Anti-Infective Products Sales Value, 2021–2032
        6.2.2 Key Countries/Regions OTC Anti-Infective Products Sales Volume, 2021–2032
    6.3 United States
        6.3.1 United States OTC Anti-Infective Products Sales Value, 2021–2032
        6.3.2 United States OTC Anti-Infective Products Sales Value by Type (%), 2025 vs 2032
        6.3.3 United States OTC Anti-Infective Products Sales Value by Sales Channel, 2025 vs 2032
    6.4 Europe
        6.4.1 Europe OTC Anti-Infective Products Sales Value, 2021–2032
        6.4.2 Europe OTC Anti-Infective Products Sales Value by Type (%), 2025 vs 2032
        6.4.3 Europe OTC Anti-Infective Products Sales Value by Sales Channel, 2025 vs 2032
    6.5 China
        6.5.1 China OTC Anti-Infective Products Sales Value, 2021–2032
        6.5.2 China OTC Anti-Infective Products Sales Value by Type (%), 2025 vs 2032
        6.5.3 China OTC Anti-Infective Products Sales Value by Sales Channel, 2025 vs 2032
    6.6 Japan
        6.6.1 Japan OTC Anti-Infective Products Sales Value, 2021–2032
        6.6.2 Japan OTC Anti-Infective Products Sales Value by Type (%), 2025 vs 2032
        6.6.3 Japan OTC Anti-Infective Products Sales Value by Sales Channel, 2025 vs 2032
    6.7 South Korea
        6.7.1 South Korea OTC Anti-Infective Products Sales Value, 2021–2032
        6.7.2 South Korea OTC Anti-Infective Products Sales Value by Type (%), 2025 vs 2032
        6.7.3 South Korea OTC Anti-Infective Products Sales Value by Sales Channel, 2025 vs 2032
    6.8 Southeast Asia
        6.8.1 Southeast Asia OTC Anti-Infective Products Sales Value, 2021–2032
        6.8.2 Southeast Asia OTC Anti-Infective Products Sales Value by Type (%), 2025 vs 2032
        6.8.3 Southeast Asia OTC Anti-Infective Products Sales Value by Sales Channel, 2025 vs 2032
    6.9 India
        6.9.1 India OTC Anti-Infective Products Sales Value, 2021–2032
        6.9.2 India OTC Anti-Infective Products Sales Value by Type (%), 2025 vs 2032
        6.9.3 India OTC Anti-Infective Products Sales Value by Sales Channel, 2025 vs 2032
7 Company Profiles
    7.1 Bayer
        7.1.1 Bayer Company Information
        7.1.2 Bayer Introduction and Business Overview
        7.1.3 Bayer OTC Anti-Infective Products Sales, Revenue, Price and Gross Margin (2021–2026)
        7.1.4 Bayer OTC Anti-Infective Products Product Offerings
        7.1.5 Bayer Recent Developments
    7.2 GSK
        7.2.1 GSK Company Information
        7.2.2 GSK Introduction and Business Overview
        7.2.3 GSK OTC Anti-Infective Products Sales, Revenue, Price and Gross Margin (2021–2026)
        7.2.4 GSK OTC Anti-Infective Products Product Offerings
        7.2.5 GSK Recent Developments
    7.3 Teva
        7.3.1 Teva Company Information
        7.3.2 Teva Introduction and Business Overview
        7.3.3 Teva OTC Anti-Infective Products Sales, Revenue, Price and Gross Margin (2021–2026)
        7.3.4 Teva OTC Anti-Infective Products Product Offerings
        7.3.5 Teva Recent Developments
    7.4 Johnson & Johnson
        7.4.1 Johnson & Johnson Company Information
        7.4.2 Johnson & Johnson Introduction and Business Overview
        7.4.3 Johnson & Johnson OTC Anti-Infective Products Sales, Revenue, Price and Gross Margin (2021–2026)
        7.4.4 Johnson & Johnson OTC Anti-Infective Products Product Offerings
        7.4.5 Johnson & Johnson Recent Developments
    7.5 NOVARTIS
        7.5.1 NOVARTIS Company Information
        7.5.2 NOVARTIS Introduction and Business Overview
        7.5.3 NOVARTIS OTC Anti-Infective Products Sales, Revenue, Price and Gross Margin (2021–2026)
        7.5.4 NOVARTIS OTC Anti-Infective Products Product Offerings
        7.5.5 NOVARTIS Recent Developments
    7.6 MYLAN
        7.6.1 MYLAN Company Information
        7.6.2 MYLAN Introduction and Business Overview
        7.6.3 MYLAN OTC Anti-Infective Products Sales, Revenue, Price and Gross Margin (2021–2026)
        7.6.4 MYLAN OTC Anti-Infective Products Product Offerings
        7.6.5 MYLAN Recent Developments
    7.7 Sun Pharma
        7.7.1 Sun Pharma Company Information
        7.7.2 Sun Pharma Introduction and Business Overview
        7.7.3 Sun Pharma OTC Anti-Infective Products Sales, Revenue, Price and Gross Margin (2021–2026)
        7.7.4 Sun Pharma OTC Anti-Infective Products Product Offerings
        7.7.5 Sun Pharma Recent Developments
    7.8 CR SANJIU
        7.8.1 CR SANJIU Company Information
        7.8.2 CR SANJIU Introduction and Business Overview
        7.8.3 CR SANJIU OTC Anti-Infective Products Sales, Revenue, Price and Gross Margin (2021–2026)
        7.8.4 CR SANJIU OTC Anti-Infective Products Product Offerings
        7.8.5 CR SANJIU Recent Developments
    7.9 Cipla
        7.9.1 Cipla Company Information
        7.9.2 Cipla Introduction and Business Overview
        7.9.3 Cipla OTC Anti-Infective Products Sales, Revenue, Price and Gross Margin (2021–2026)
        7.9.4 Cipla OTC Anti-Infective Products Product Offerings
        7.9.5 Cipla Recent Developments
    7.10 Lingrui
        7.10.1 Lingrui Company Information
        7.10.2 Lingrui Introduction and Business Overview
        7.10.3 Lingrui OTC Anti-Infective Products Sales, Revenue, Price and Gross Margin (2021–2026)
        7.10.4 Lingrui OTC Anti-Infective Products Product Offerings
        7.10.5 Lingrui Recent Developments
    7.11 Gilead Sciences
        7.11.1 Gilead Sciences Company Information
        7.11.2 Gilead Sciences Introduction and Business Overview
        7.11.3 Gilead Sciences OTC Anti-Infective Products Sales, Revenue, Price and Gross Margin (2021–2026)
        7.11.4 Gilead Sciences OTC Anti-Infective Products Product Offerings
        7.11.5 Gilead Sciences Recent Developments
    7.12 Pfizer
        7.12.1 Pfizer Company Information
        7.12.2 Pfizer Introduction and Business Overview
        7.12.3 Pfizer OTC Anti-Infective Products Sales, Revenue, Price and Gross Margin (2021–2026)
        7.12.4 Pfizer OTC Anti-Infective Products Product Offerings
        7.12.5 Pfizer Recent Developments
    7.13 Bausch Health
        7.13.1 Bausch Health Company Information
        7.13.2 Bausch Health Introduction and Business Overview
        7.13.3 Bausch Health OTC Anti-Infective Products Sales, Revenue, Price and Gross Margin (2021–2026)
        7.13.4 Bausch Health OTC Anti-Infective Products Product Offerings
        7.13.5 Bausch Health Recent Developments
    7.14 Astellas Pharma
        7.14.1 Astellas Pharma Company Information
        7.14.2 Astellas Pharma Introduction and Business Overview
        7.14.3 Astellas Pharma OTC Anti-Infective Products Sales, Revenue, Price and Gross Margin (2021–2026)
        7.14.4 Astellas Pharma OTC Anti-Infective Products Product Offerings
        7.14.5 Astellas Pharma Recent Developments
    7.15 Roche
        7.15.1 Roche Company Information
        7.15.2 Roche Introduction and Business Overview
        7.15.3 Roche OTC Anti-Infective Products Sales, Revenue, Price and Gross Margin (2021–2026)
        7.15.4 Roche OTC Anti-Infective Products Product Offerings
        7.15.5 Roche Recent Developments
8 Industry Chain Analysis
    8.1 OTC Anti-Infective Products Industrial Chain
    8.2 OTC Anti-Infective Products Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Key Suppliers of Raw Materials
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customer Analysis)
    8.5 Sales Model and Sales Channelss
        8.5.1 OTC Anti-Infective Products Sales Model
        8.5.2 Sales Channels
        8.5.3 OTC Anti-Infective Products Distributors
9 Research Findings and Conclusion
10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
            10.1.1.1 Research Programs/Design
            10.1.1.2 Market Size Estimation
            10.1.1.3 Market Breakdown and Data Triangulation
        10.1.2 Data Source
            10.1.2.1 Secondary Sources
            10.1.2.2 Primary Sources
    10.2 Author Details
    10.3 Disclaimer
title

Table of Figures

List of Tables
 Table 1. OTC Anti-Infective Products Market Trends
 Table 2. OTC Anti-Infective Products Market Drivers & Opportunities
 Table 3. OTC Anti-Infective Products Market Challenges
 Table 4. OTC Anti-Infective Products Market Restraints


List of Figures
 Figure 1. OTC Anti-Infective Products Product Picture
 Figure 2. Global OTC Anti-Infective Products Sales Value, 2021 vs 2025 vs 2032 (US$ Million)
 Figure 3. Global OTC Anti-Infective Products Sales Value (US$ Million), 2021–2032
 Figure 4. Global OTC Anti-Infective Products Sales Volume (M Units), 2021–2032
 Figure 5. Global OTC Anti-Infective Products Sales Price (US$/Unit), 2021–2032
 Figure 6. OTC Anti-Infective Products Report Years Considered
 Figure 7. Global OTC Anti-Infective Products Players Revenue Ranking (US$ Million), 2025
 Figure 8. Global OTC Anti-Infective Products Sales Volume Ranking of Players (M Units), 2025
 Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by OTC Anti-Infective Products Revenue in 2025
 Figure 10. OTC Anti-Infective Products Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 11. Antifungal Picture
 Figure 12. Antibacterial Picture
 Figure 13. Antiviral Picture
 Figure 14. Antiseptics Picture
 Figure 15. Others Picture
 Figure 16. Global OTC Anti-Infective Products Sales Value by Type (US$ Million), 2021 vs 2025 vs 2032
 Figure 17. Global OTC Anti-Infective Products Sales Value Market Share by Type, 2025 & 2032
 Figure 18. Global OTC Anti-Infective Products Sales Volume by Type (M Units), 2021 vs 2025 vs 2032
 Figure 19. Global OTC Anti-Infective Products Sales Volume Market Share by Type, 2025 & 2032
 Figure 20. Global OTC Anti-Infective Products Price by Type (US$/Unit), 2021–2032
 Figure 21. Product Picture of Hospital Pharmacies
 Figure 22. Product Picture of Retail Pharmacies
 Figure 23. Product Picture of Online Pharmacies
 Figure 24. Global OTC Anti-Infective Products Sales Value by Sales Channel (US$ Million), 2021 vs 2025 vs 2032
 Figure 25. Global OTC Anti-Infective Products Sales Value Market Share by Sales Channel, 2025 & 2032
 Figure 26. Global OTC Anti-Infective Products Sales Volume by Sales Channel (M Units), 2021 vs 2025 vs 2032
 Figure 27. Global OTC Anti-Infective Products Sales Volume Market Share by Sales Channel, 2025 & 2032
 Figure 28. Global OTC Anti-Infective Products Price by Sales Channel (US$/Unit), 2021–2032
 Figure 29. North America OTC Anti-Infective Products Sales Value (US$ Million), 2021–2032
 Figure 30. North America OTC Anti-Infective Products Sales Value by Country (%), 2025 vs 2032
 Figure 31. Europe OTC Anti-Infective Products Sales Value (US$ Million), 2021–2032
 Figure 32. Europe OTC Anti-Infective Products Sales Value by Country (%), 2025 vs 2032
 Figure 33. Asia Pacific OTC Anti-Infective Products Sales Value (US$ Million), 2021–2032
 Figure 34. Asia Pacific OTC Anti-Infective Products Sales Value by Region (%), 2025 vs 2032
 Figure 35. South America OTC Anti-Infective Products Sales Value (US$ Million), 2021–2032
 Figure 36. South America OTC Anti-Infective Products Sales Value by Country (%), 2025 vs 2032
 Figure 37. Middle East & Africa OTC Anti-Infective Products Sales Value (US$ Million), 2021–2032
 Figure 38. Middle East & Africa OTC Anti-Infective Products Sales Value by Country (%), 2025 vs 2032
 Figure 39. Key Countries/Regions OTC Anti-Infective Products Sales Value (%), 2021–2032
 Figure 40. Key Countries/Regions OTC Anti-Infective Products Sales Volume (%), 2021–2032
 Figure 41. United States OTC Anti-Infective Products Sales Value (US$ Million), 2021–2032
 Figure 42. United States OTC Anti-Infective Products Sales Value by Type (%), 2025 vs 2032
 Figure 43. United States OTC Anti-Infective Products Sales Value by Sales Channel (%), 2025 vs 2032
 Figure 44. Europe OTC Anti-Infective Products Sales Value (US$ Million), 2021–2032
 Figure 45. Europe OTC Anti-Infective Products Sales Value by Type (%), 2025 vs 2032
 Figure 46. Europe OTC Anti-Infective Products Sales Value by Sales Channel (%), 2025 vs 2032
 Figure 47. China OTC Anti-Infective Products Sales Value (US$ Million), 2021–2032
 Figure 48. China OTC Anti-Infective Products Sales Value by Type (%), 2025 vs 2032
 Figure 49. China OTC Anti-Infective Products Sales Value by Sales Channel (%), 2025 vs 2032
 Figure 50. Japan OTC Anti-Infective Products Sales Value (US$ Million), 2021–2032
 Figure 51. Japan OTC Anti-Infective Products Sales Value by Type (%), 2025 vs 2032
 Figure 52. Japan OTC Anti-Infective Products Sales Value by Sales Channel (%), 2025 vs 2032
 Figure 53. South Korea OTC Anti-Infective Products Sales Value (US$ Million), 2021–2032
 Figure 54. South Korea OTC Anti-Infective Products Sales Value by Type (%), 2025 vs 2032
 Figure 55. South Korea OTC Anti-Infective Products Sales Value by Sales Channel (%), 2025 vs 2032
 Figure 56. Southeast Asia OTC Anti-Infective Products Sales Value (US$ Million), 2021–2032
 Figure 57. Southeast Asia OTC Anti-Infective Products Sales Value by Type (%), 2025 vs 2032
 Figure 58. Southeast Asia OTC Anti-Infective Products Sales Value by Sales Channel (%), 2025 vs 2032
 Figure 59. India OTC Anti-Infective Products Sales Value (US$ Million), 2021–2032
 Figure 60. India OTC Anti-Infective Products Sales Value by Type (%), 2025 vs 2032
 Figure 61. India OTC Anti-Infective Products Sales Value by Sales Channel (%), 2025 vs 2032
 Figure 62. OTC Anti-Infective Products Industrial Chain
 Figure 63. OTC Anti-Infective Products Manufacturing Cost Structure
 Figure 64. Channels of Distribution (Direct Sales, and Distribution)
 Figure 65. Bottom-up and Top-down Approaches for This Report
 Figure 66. Data Triangulation
 Figure 67. Key Executives Interviewed

お見積>

サンプルお申込み>

今すぐ購入>

PDFダウンロード>

当社から購入のメリット
  • jiantou

    多言語（英語、日本語）のサンプル提供

  • jiantou

    プロフェッショナルな日本語翻訳を提供

  • jiantou

    請求書、クレジットカードでのお支払いが可能です

  • jiantou

    必要なチャプターやカスタマイズされたレポートの注文が可能

  • jiantou

    購入後、アナリストに直接連絡することができます

購入方法
shunxu

  • 必要な言語とバージョンのレポート選択

  • レポート要件と見積もり依頼

  • 電子メールによる注文

  • レポートの入手（英語版は2～4営業日、日本語版は8～10営業日）

  • クレジットカード決済、オフライン振込に対応（後払い可）

※当サイトに掲載されていない海外調査報告書も当社経由でご購入いただけますので、お問い合わせください。

※市場調査レポートの購入や市場調査をご希望の場合は、実績と信頼のある株式会社市場調査センターにお任せください。

*フォーチュン500企業は当社と緊密な協力関係を確立しています

クライアント様（例）
ご利用ガイド
利用規約よくあるご質問プライバシーポリシー支払い方法と購入ガイド
お電話でのお問い合わせ
email050-5840-2692 日本
email0081-50-5840-2692 グローバル
9:00-18:00 (土日・祝日を除く)
底部logo
Copyright 2016-2026 Global Reports著作権所有